NEW YORK (GenomeWeb News) – Life Technologies today said that it has signed a licensing and supply deal with VelaDx providing the Singapore-based firm rights to develop clinical diagnostic tests on Life Tech's Ion Personal Genome Machine platform.

Under the terms of the deal VelaDx will seek regulatory approvals from global authorities to sell clinical tests for oncology and infectious disease applications. Further terms of the alliance were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.